Eli Lilly recently announced the development of a revolutionary new weight loss drug called Tirzepatide. This new drug is the first of its kind to target both the hunger and satiety hormones in the body, providing a more effective way to lose weight.
Tirzepatide works by targeting the two hormones, ghrelin and GLP-1. Ghrelin is the hormone that tells your brain when you’re hungry, while GLP-1 is the hormone that signals when you’re full. By targeting both of these hormones, Tirzepatide helps to reduce hunger and increase satiety so that people can eat less and feel fuller for longer.
In addition to the weight loss benefits, Tirzepatide also has the potential to help people with type 2 diabetes. The drug works by helping to reduce blood sugar levels, which can help to improve glycemic control and reduce the risk of complications associated with diabetes.
Eli Lilly is currently conducting clinical trials of Tirzepatide and hopes to have the drug available for prescription by the end of 2021. The drug is expected to be available in both pill and injectable form.
Eli Lilly’s Tirzepatide is a revolutionary new weight loss drug that has the potential to help people lose weight and improve glycemic control in those with type 2 diabetes. The drug works by targeting both hunger and satiety hormones, helping to reduce hunger and increase satiety. Eli Lilly is currently conducting clinical trials of the drug and hopes to have it available for prescription by the end of 2021.